REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.99 USD | -0.12% |
|
+3.56% | -10.92% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 98.66M | Sales 2025 * | 268M | Capitalization | 788M |
|---|---|---|---|---|---|
| Net income 2024 * | -232M | Net income 2025 * | -73M | EV / Sales 2024 * | 6.95 x |
| Net cash position 2024 * | 102M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 2.36 x |
| P/E ratio 2024 * |
-3.23
x | P/E ratio 2025 * |
-11.4
x | Employees | 344 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on REGENXBIO Inc.
More recommendations
More press releases
| 1 day | -0.12% | ||
| 1 week | +3.56% | ||
| Current month | +4.17% | ||
| 1 month | -0.74% | ||
| 3 months | -15.08% | ||
| 6 months | -17.96% | ||
| Current year | -10.92% |
1 week
15.42
16.85
1 month
14.8717.52
Current year
11.8328.80
1 year
11.8328.80
3 years
11.8346.46
5 years
11.8355.23
10 years
7.0785.10
| Managers | Title | Age | Since |
|---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 09-07-31 |
| Chief Tech/Sci/R&D Officer | - | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 21-09-02 |
David Stump
BRD | Director/Board Member | 74 | 15-10-14 |
| Director/Board Member | 71 | 15-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 14 M€ | -3.66% | ||
| 0.25% | 25 M€ | -1.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 15.99 | -0.12% | 312,676 |
| 24-05-16 | 16.01 | -1.36% | 380,728 |
| 24-05-15 | 16.23 | +2.72% | 401,011 |
| 24-05-14 | 15.8 | +0.38% | 369,317 |
| 24-05-13 | 15.74 | +1.94% | 483,961 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
15.99
USD
Average target price
39.25
USD
Spread / Average Target
+145.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.92% | 788M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- RGNX Stock
